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Abstract This review summarizes recent findings on the
metabolism and biological functions of saturated fatty
acids (SFA). Some of these findings show that SFA may
have important and specific roles in the cells. Elucidated
biochemical mechanisms like protein acylation (N-myris-
toylation, S-palmitoylation) and regulation of gene tran-
scription are presented. In terms of physiology, SFA are
involved for instance in lipogenesis, fat deposition, poly-
unsaturated fatty acids bioavailability and apoptosis. The
variety of their functions demonstrates that SFA should no
longer be considered as a single group.




NMT Myristoyl–CoA: protein N-myristoyltransferase
PL Phospholipids
PUFA Polyunsaturated fatty acids
SCD Stearoyl–CoA desaturase
SFA Saturated fatty acids
TAG Triglycerides
Introduction
Observational studies have shown that high intake of sat-
urated fatty acids (SFA) is positively associated with
increased levels of blood cholesterol and high coronary
heart disease mortality rates [1, 2]. However, more recent
studies have shown inverse association [3, 4], and the
meta-analysis by Siri-Tarino et al. [5] reopened the debate
when writing that ‘‘there is no significant evidence for
concluding that dietary saturated fat is associated with an
increased risk of CHD or CVD’’. Without entering this
interesting epidemiological debate on the deleterious
effects of some of saturated fatty acids, it seems that they
can be no longer considered as a single group in terms of
structure, metabolism [6, 7] and cellular function. In this
context, this review will focus only on recent findings
suggesting that individual SFA possess specific properties
associated with important biological functions.
New Aspects on the Metabolism of Saturated Fatty
Acids
Cellular Origin of Saturated Fatty Acids
SFA usually account for 30–40% of total FA in animal
tissues, distributed in palmitic acid (15–25%), stearic acid
(10–20%), myristic acid (0.5–1%) and lauric acid (less than
0.5%). Palmitic and stearic acids are universally found in
natural fats. Lauric acid is specifically abundant in copra
(39–54%) and palmist oils (44–51%). Myristic acid and
short-chain fatty acids (including butyric acid) represent
each about 10% of FA in milk fat. Apart from the dietary
sources, it is well known that the body is capable of syn-
thesizing SFA. Because of their multiple potential origins,
it has been difficult to quantify the real importance of
dietary SFA when compared with endogenous SFA, espe-
cially for palmitic acid. Adipose tissue concentrations of
C15:0, C17:0 but also C14:0 have been used as quantitative
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markers of dairy consumption [8]. With regard to myristic
acid, the amount of its endogenous biosynthesis [9] is
indeed far smaller than the amounts consumed from dietary
sources (4 g/day in a Swedish population) [10].
Desaturation of Saturated Fatty Acids
Recent findings on SFA concern their respective capacities
to be desaturated. Every SFA from C12:0 to C18:0 is
converted to its respective monounsaturated product
through the action of D9-desaturase (Stearoyl–CoA desat-
urase, SCD) but with varying efficiency. In the rat [11], a
clear increase in hepatic D9-desaturase activity is related to
the carbon chain length, from C12:0 to C18:0. Evidence
was also recently presented that palmitic acid, already
known as a substrate of D9-desaturase, can also be desat-
urated by the mammalian D6-desaturase (Fatty acid
desaturase 2: FADS2) [12]. Palmitic acid D6-desaturation
produces sapienic acid (C16:1n-10) in the preputial gland
of SCD1-/- mice [13] and in human sebaceous glands in
which the expression of SCD is low [14]. The importance
of this human physiological specificity remains to be
determined.
Specific Biochemical Functions of Individual SFA
Regulation of Protein Activation by N-terminal
Myristoylation
Myristic and palmitic acids are directly involved in the two
classes of protein fatty acid acylation, N-terminal myris-
toylation and side-chain palmitoylation [15]. Protein
N-myristoylation (Fig. 1) refers to the highly specific
covalent attachment of myristic acid, by an amide linkage,
to the NH2-terminal glycine residue of increasing number
of eukaryotic and viral proteins [16]. Myristoyl–CoA:
protein N-myristoyltransferase (NMT, EC 2.3.1.97), the
enzyme catalyzing this stable acylation, has been identified
in many organisms. Genetic advances have revealed that
mammals possess two distinct NMT genes, named type 1
and 2 [17–19]. The contribution of each gene transcript to
NMT expression and activity in vivo, and the specific role
of each NMT isoform in cellular replication, proliferation,
and other cellular processes, is still under investigation
[20–22]. They both seem to have a similar high substrate
selectivity for myristic acid [17, 19]. The myristoyl moiety
has been shown to mediate protein subcellular localization,
protein–protein interaction or protein–membrane interac-
tions (Fig. 1) required for the biological activities of the
myristoylated proteins [16]. In the myristoylation pathway,
myristic acid therefore exhibits a specific and important
role for protein activation.
The proteins that are substrates of NMT include key
components in intracellular signaling pathways, onco-
genes, structural viral proteins, and common constitutive
eukaryotic proteins. Computational prediction recently
suggested that about 0.5% of all proteins in the human
genome could be myristoylated [23]. New protein sub-
strates identified recently in mammals are the tumor
suppressor Fus1 [24], TRIF [25], the sphingolipid D4-
desaturases type 1 and 2 [26], and truncated protein forms
that become substrates after post-translational cleavage by
caspases that reveals an internal myristoylation motif:
BID [27], actin [28], gelsolin [29], and p21-activated
protein kinase 2 [30].
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Can Myristic Acid be the Rate-Limiting Molecule
in the Myristoylation Pathway?
Since endogenous biosynthesis of C14:0 [9] is very low as
compared with dietary sources [10], one can ask if the
amount of free myristic acid could be insufficient to pro-
vide myristoyl–CoA: protein N-NMT with enough co-
substrate. In yeast, studies analyzing the activity of NMT
have suggested that the enzyme was able to use both
exogenous and endogenous myristic acid as the substrate
[31–33]. During the process of the maturation of one pro-
tein, the pool of endogenous free myristoyl–CoA would
probably be sufficient [34]. However, when considering the
pool of myristoylable proteins or the specific process for
the maturation of viral proteins like Gag or Nef during the
course of a viral, retroviral or lentiviral infection, the
amount of myristoyl–CoA co-substrate needed is consid-
erable [35]. The requirement for myristic acid suggests that
in certain cases, it could be the rate-limiting molecule in
this mechanism or that competition could occur. In addi-
tion, the mechanism by which myristic acid initially
esterified in the TAG or PL is used for myristoylation is
unknown, too. The available evidence indicates that the
intracellular concentration of free myristic acid in endo-
thelial cells is crucial for the activation of thrombospondin-
1 and could be modulated by its uptake from the medium
through CD36 [36].
Regulation of Protein–Membrane Interactions
by Palmitoylation
Protein palmitoylation refers to the post-translational for-
mation of a thioester linkage between the side-chain of
cysteine and palmitic acid, mainly [37], or other saturated
fatty acids, like myristic and lauric acids [38]. A long time
ago, the ester linkage between saturated fatty acids and
serine or threonine residues was also reported [39], but
since then, this type of linkage has not been described
again.
Palmitoylation is involved in regulatory mechanisms
because the association of the protein with the palmitoyl
moiety is reversible and facilitates protein–membrane
interactions and subcellular trafficking of proteins.
Several signal transductions depend therefore on pal-
mitic acid, including proteins that have been shown to
undergo successive myristoylation and palmitoylation,
like the a subunit of many heterotrimeric G proteins
[40]. Mammalian protein palmitoyltransferases (also
named Protein S-AcylTransferases PAT) are still under
investigation [37]. The recent biochemical evidence of
the PAT activity of a family of proteins that share a
DHHC motif in yeast [41–43] has opened a new field of
investigation.
Regulation of Gene Transcription by Saturated Fatty
Acids
While dietary PUFA are known to regulate gene expression
through their influence on transcription factors (PPAR,
SREBP), the effect of SFA on gene transcription has been
less explored. Lin et al. [44] have shown that SFA (C10:0–
C18:0) strongly elevate the PGC-1b mRNA level, that
co-activates the action of SREBP family of transcription
factors, and consequently increase the transcription of
lipogenic target genes (FAS, SCD-1). Co-activation of the
nuclear receptor LXR/RXR also promotes VLDL secre-
tion. SFA (but also monounsaturated FA) are known to
bind hepatocyte nuclear factor 4 (HNF4). In liver cells,
palmitate and oleate both enhanced the transcription of
glucose-6-phosphatase gene. Palmitate also induced the
recruitment of several transcription factors like NF-jB,
HNF4, CEBPa, and PPARa [45]. SFA, when linked to the
lipid A moiety of lipopolysaccharides, or free, also indi-
rectly induce NF-jB nuclear translocation, activation and
expression of COX-2, and other pro-inflammatory cytokines,
through the recently described toll-like receptor 4-derived
signaling pathways [46, 47]. Finally, because it is an inhibitor
of the histone deacetylase activity, butyric acid regulates the
expression of several genes, like IL5, by altering the histone
acetylating status of their promoter regions, with conse-
quences for the structure of chromatin [48, 49].
New Demonstrated or Putative Physiological Roles
of SFA
Stearic Acid is Neutral for Cholesterol but Could be
Pro-Lipogenic
As for the other long-chain saturated fatty acids, the health
impact of stearic acid has been studied, showing no deleteri-
ous effect on cardiovascular disease risk [50, 51]. The high
rate of C18:0 conversion to C18:1n-9 by D9-desaturation was
suggested to explain this neutral effect on cholesterol
metabolism, compared to the other SFA [52]. On the other
hand, the desaturation of dietary stearate to endogenous oleate
has been described as a stimulating factor for VLDL–TAG
secretion in hepatocytes [53], and an essential step mediating
the induction of lipogenesis [54] and the promotion of obesity
[55], showing the very important role of SCD. The evidence
concerning the putative effect of stearic acid on thrombotic
tendency appears inconsistent [56, 57].
Myristic Acid Could Regulate PUFA Bioavailability
It has recently been suggested that myristic acid may be an
activator of the conversion of a-linolenic acid to
Lipids (2010) 45:941–946 943
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docosahexaenoic acid (DHA). In cultured rat hepatocytes,
myristic acid had a specific and dose-dependent effect on
D6-desaturase activity [58]. In vivo, when myristic acid
was supplied for 2 months in the diet of rats (from 0.2 to
1.2% of dietary energy), with similar level of dietary
a-linolenic acid (1.6% of FA, 0.3% of energy), a dose–
response accumulation of eicosapentaenoic acid (EPA) was
shown in the liver and plasma [59].
In addition, in humans, compared with a diet containing
0.6% of myristic acid mainly in the sn-2 position in the
TAG, a diet containing 1.2% of myristic acid during a
5-week consumption period significantly enhanced EPA
and DHA levels in the plasma PL and DHA level in the
plasma cholesteryl esters [60]. When the intake of myristic
acid increased from 1.2 to 1.8% energy in the same pop-
ulation, EPA, DPA and DHA decreased significantly in
plasma PL and EPA also decreased in cholesteryl esters
[61]. This result suggest that, in humans, the effect of
myristic acid on circulating (n-3) PUFA follows a U-
shaped curve with a favorable turning point at around 1.2%
of total daily energy.
So far as potential mechanism(s) of action are con-
cerned, the increase in the activity of D6-desaturase by
myristic acid was first postulated to be mediated by
N-myristoylation (see below) because this enzyme exhibits an
N-terminal glycine residue. However, we recently demon-
strated that D6-desaturase is not myristoylated in vivo [26].
The hypothesis has been proposed that myristoylation of
another protein of the whole complex of D6-desaturation,
NADH cytochrome b5 reductase [62], could account for this
increased activity.
Lauric Acid Could be a Precursor for x3 Fatty Acid
Biosynthesis
The low level of C12:0 conversion to C12:1n-3 in the liver
of rats has led to the hypothesis that this monounsaturated
fatty acid of the (n-3) series might be, under extreme
physiological circumstances [for example animals deprived
of (n-3) PUFA in the diet during a long period], an unusual
precursor for the biosynthesis of a-linolenic acid, by suc-
cessive D6-desaturation, elongation, D5-desaturation and
two final elongations [11].
SFA May Play Multiple Roles in Early Events
of Apoptosis
Specific histone deacetylase inhibitors, like butyric acid,
selectively induce cellular differentiation, growth arrest and
apoptosis in a variety of cancer cells [63]. Although contra-
dictory effects have been reported [64], it seems that delivery
of an adequate amount of butyrate to the appropriate site could
protect against early tumorigenic events [65].
Several SFA may induce apoptosis via different ways.
First, as already suggested above, butyrate and short-chain
SFA may also have an effect on apoptosis [66]. Second,
the pro-apoptotic effect of non-esterified palmitate and
stearate was shown to require acyl–CoA formation and
NF-jB activation [67]. Third, SFA may also influence
apoptosis via the ceramide pathway by inducing ceramide
de novo synthesis at several steps [68–70]. The first step
catalyzed by the serine palmitoyltransferase involves ser-
ine condensation with palmitoyl–CoA [71]. The last step is
catalyzed by dihydroceramide D4-desaturase (DES). We
recently showed that both DES1 and DES2 isoforms are
myristoylated and that this N-terminal modification sig-
nificantly increased the activity of recombinant DES1 in
COS-7 cells [26]. Compared with a recombinant unmyri-
stoylable mutant form of DES1 (N-terminal glycine
replaced by an alanine), the desaturase activity of the
myristoylable wild-type DES1 was two times higher, in
the presence of myristic acid incubated with the cells [26].
The description of this regulatory mechanism highlighted
a new potential relationship between myristic acid, the
saturated fatty acid capable of binding and activating the
enzyme involved in the final de novo ceramide biosyn-
thesis step, and lipoapoptosis induced through the cera-
mide pathway. Therefore, we subsequently hypothesized
and showed that the myristoylation of recombinant DES 1
can target part of the enzyme to the mitochondria, leading
to an increase in ceramide levels (specifically in the
mitochondria) which in turn leads to apoptosis in the COS-
7 cell model [72].
Medium-Chain Fatty Acids and Fat Deposition
A point of interest is the specific role played by medium-
chain SFA. It has been reported that overfeeding with a
medium-chain TAG diet in rats results in a diminished
deposition of fat, when compared with rats overfed with
isocaloric long-chain TAG [73]. This suggests an obliga-
tory oxidation of medium-chain SFA in the liver, after
transport via the portal vein, leaving no medium-chain
TAG for accumulation in adipose tissue [73]. Another
hypothesis for medium-chain TAG effect is their inhibitory
effect on apoB synthesis, reducing the VLDL secretion by
hepatocytes. This has been observed with octanoate in
chicken hepatocytes [74].
Conclusion
We have reported here new knowledge on cellular and
physiological functions of the different SFA. For this rea-
son, SFA should no longer be considered as a single group
in terms of structure, metabolism, and function.
944 Lipids (2010) 45:941–946
123
References
1. Keys A (1970) Coronary heart disease in seven countries.
Circulation 41:1–211
2. Kromhout D, Bloemberg B, Feskens E, Menotti A, Nissinen A
(2000) Saturated fat, vitamin C and smoking predict long-term
population all-cause mortality rates in the seven countries study.
Int J Epidemiol 29:260–265
3. Gillman MW, Cupples LA, Millen BE, Ellison RC, Wolf PA
(1997) Inverse association of dietary fat with development of
ischemic stroke in men. JAMA 278:2145–2150
4. Mozaffarian D, Rimm EB, Herrigton DM (2004) Dietary fats,
carbohydrate, and the progression of coronary atherosclerosis in
post menopausal women. Am J Clin Nutr 80:1175–1184
5. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM (2010) Meta-analysis
of prospective cohort studies evaluating the association of satu-
rated fat with cardiovascular disease. Am J Clin Nutr 91:535–546
6. Hughes TA, Heimberg M, Wang X, Wilcox H, Hughes SM,
Tolley EA, Desiderio DM, Dalton JT (1996) Comparative lipo-
protein metabolism of myristate, palmitate, and stearate in nor-
molipidemic men. Metabolism 45:1108–1118
7. Rioux V, Lemarchal P, Legrand P (2000) Myristic acid, unlike
palmitic acid, is rapidly metabolized in cultured rat hepatocytes.
J Nutr Biochem 11:198–207
8. Warensjo¨ E, Jansson JH, Berglund L, Boman K, Ahren B, Weinehall
L, Lindahl B, Hallmans G, Vessby B (2004) Estimated intake of milk
fat is negatively associated with cardiovascular risk factors and does
not increase the risk of a first acute myocardial infarction. A pro-
spective case-control study. Br J Nutr 91:635–642
9. Rioux V, Catheline D, Legrand P (2007) In rat hepatocytes,
myristic acid occurs through lipogenesis, palmitic acid shortening
and lauric acid elongation. Animal 1:820–826
10. Wolk A, Furuheim M, Vessby B (2001) Fatty acid composition of
adipose tissue and serum lipids are valid biological markers of
dairy fat intake in men. J Nutr 131:828–833
11. Legrand P, Catheline D, Rioux V, Durand G (2002) Lauric acid is
desaturated to C12:1n-3 by rat liver homogenate and hepatocytes.
Lipids 37:569–572
12. Guillou H, Rioux V, Catheline D, Thibault JN, Bouriel M, Jan S,
D’Andrea S, Legrand P (2003) Conversion of hexadecanoic acid
to hexadecenoic acid by rat D6-desaturase. J Lipid Res
44:450–454
13. Miyazaki M, Gomez FE, Ntambi JM (2002) Lack of stearoyl–
CoA desaturase-1 function induces a palmitoyl-CoA delta-6
desaturase and represses the stearyl–CoA desaturase-3 gene in the
preputial glands of the mouse. J Lipid Res 43:2146–2154
14. Ge L, Gordon JS, Hsuan C, Stenn K, Prouty SM (2003) Identi-
fication of the delta-6 desaturase of human sebaceous glands:
expression and enzyme activity. J Invest Dermatol 120:707–714
15. Towler DA, Gordon JI, Adams SP, Glaser L (1988) The biology
and enzymology of eukaryotic protein acylation. Annu Rev
Biochem 57:69–99
16. Johnson DR, Bhatnagar RS, Knoll LJ, Gordon JI (1994) Genetic
and biochemical studies of protein N-myristoylation. Annu Rev
Biochem 63:869–914
17. Giang DK, Cravatt BF (1998) A second mammalian N-myri-
stoyltransferase. J Biol Chem 273:6595–6598
18. Rundle DR, Rajala RVS, Anderson RE (2002) Characterization
of type I and type II myristoyl–CoA: protein N-myristoyltrans-
ferase with the acyl–CoAs found on heterogeneously acylated
retinal proteins. Exp Eye Res 75:87–97
19. Rioux V, Beauchamp E, Pedrono F, Daval S, Molle D, Catheline
D, Legrand P (2006) Identification and characterization of
recombinant and native rat myristoyl–CoA: protein N-myri-
stoyltransferases. Mol Cell Biochem 286:161–170
20. Yang SH, Shrivastav A, Kosinski C, Sharma RK, Chen MH,
Berthiaume LG, Peters LL, Chuang PT, Young SG, Bergo MO
(2005) N-myristoyltransferase 1 is essential in early mouse
development. J Biol Chem 280:18990–18995
21. Ducker CE, Upson JJ, French KJ, Smith CD (2005) Two
N-myristoyltransferase isozymes play unique roles in protein
myristoylation, proliferation, and apoptosis. Mol Cancer Res
3:463–476
22. Selvakumar P, Smith-Windsor E, Bonham K, Sharma RK (2006)
N-myristoyltransferase 2 expression in human colon cancer:
cross-talk between the calpain and caspase system. FEBS Lett
580:2021–2026
23. Maurer-Stroh S, Gouda M, Novatchkova M, Schleiffer A,
Schneider G, Sirota FL, Wildpaner M, Hayashi N, Eisenhaber F
(2004) MYRbase: analysis of genome-wide glycine myristoyla-
tion enlarges the functional spectrum of eukaryotic myristoylated
proteins. Genome Biol 5:1–16
24. Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Atkinson EN,
Kondo M, Minna JD, Roth JA, Ji L (2004) Myristoylation of Fus1
protein is required for tumor suppression in human lung cancer
cells. Cancer Res 64:2969–2976
25. Rowe DC, McGettrick AF, Latz E, Monks BG, Gay NJ,
Yamamoto M, Akira S, O’Neill LA, Fitzgerald KA, Golenbock
DT (2006) The myristoylation of TRIF-related molecule is
essential for toll-like receptor 4 signal transduction. Proc Natl
Acad Sci USA 103:6399–6404
26. Beauchamp E, Goenaga D, Le Bloc’h J, Catheline D, Legrand P,
Rioux V (2007) Myristic acid increases the activity of dihydro-
ceramide D4-desaturase 1 through its N-terminal myristoylation.
Biochimie 89:1553–1561
27. Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ (2000) Post-
translational N-myristoylation of BID as a molecular switch for
targeting mitochondria and apoptosis. Science 290:1761–1765
28. Utsumi T, Sakurai N, Nakano K, Ishisaka R (2003) C-terminal
15 kDa fragment of cytoskeletal actin is posttranslationally
N-myristoylated upon caspase-mediated cleavage and targeted to
mitochondria. FEBS Lett 539:37–44
29. Sakurai N, Utsumi T (2006) Posttranslational N-myristoylation is
required for the anti-apoptotic activity of human tGelsolin, the
C-terminal caspase cleavage product of human gelsolin. J Biol
Chem 281:14288–14295
30. Vilas GL, Corvi MM, Plummer GJ, Seime AM, Lambkin GR,
Berthiaume LG (2006) Posttranslational myristoylation of cas-
pase-activated p21-activated protein kinase 2 (PAK2) potentiates
late apoptotic events. Proc Natl Acad Sci USA 103:6542–6547
31. Duronio RJ, Rudnick DA, Johnson RL, Johnson DR, Gordon JI
(1991) Myristic acid auxotrophy caused by mutation of S. cere-
visiae myristoyl–CoA: protein N-myristoyltransferase. J Cell Biol
113:1313–1330
32. Duronio RJ, Reed SI, Gordon JI (1992) Mutations of human
myristoyl–CoA: protein N-myristoyltransferase cause tempera-
ture-sensitive myristic auxotrophy in Saccharomyces cerevisiae.
Proc Natl Acad Sci USA 89:4129–4133
33. Johnson DR, Knoll LJ, Levin DE, Gordon JI (1994) Saccharo-
myces cerevisiae contains four fatty acid activation (FAA) genes:
an assessment of their role in regulating protein N-myristoylation
and cellular lipid metabolism. J Cell Biol 127:751–762
34. Boutin JA (1997) Myristoylation. Cell Signal 9:15–35
35. Hill BT, Skowronski J (2005) Human N-myristoyltransferases
form stable complexes with lentiviral nef and other viral and
cellular substrate proteins. J Virol 79:1133–1141
36. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, Roberts
DD (2007) Thrombospondin-1 inhibits nitric oxide signaling via
CD36 by inhibiting myristic acid uptake. J Biol Chem
282:15404–15415
Lipids (2010) 45:941–946 945
123
37. Mitchell DA, Vasudevan A, Linder ME, Deschenes RJ (2006)
Protein palmitoylation by a family of DHHC protein S-acyl-
transferases. J Lipid Res 47:1118–1127
38. Rioux V, Galat A, Jan G, Vinci F, d’Andrea S, Legrand P (2002)
Exogenous myristic acid acylates proteins in cultured rat hepa-
tocytes. J Nutr Biochem 13:66–74
39. Grand RJA (1989) Acylation of viral and eukaryotic proteins.
Biochem J 258:625–638
40. Chen CA, Manning DR (2001) Regulation of G proteins by
covalent modification. Oncogene 20:1643–1652
41. Lobo S, Greentree WK, Linder ME, Deschenes RJ (2002) Iden-
tification of a Ras palmitoyltransferase in Saccharomyces cere-
visiae. J Biol Chem 277:41268–41273
42. Roth AF, Feng Y, Chen L, Davis NG (2002) The yeast DHHC
cysteine-rich domain protein Akr1p is a palmitoyl transferase.
J Cell Biol 159:23–28
43. Smotrys JE, Schoenfish MJ, Stutz MA, Linder ME (2005) The
vacuolar DHHC-CRD protein Pfa3p is a protein acyltransferase
for Vac8p. J Cell Biol 170:1091–1099
44. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, Li S, Yang W, Pei
L, Uldry M, Tontonoz P, Newgard CB, Spiegelman BM (2005)
Hyperlipidemic effects of dietary saturated fats mediated through
PGC-1beta coactivation of SREBP. Cell 120:261–273
45. Xu C, Chakravarty K, Kong X, Tuy TT, Arinze IJ, Bone F,
Massillon D (2007) Several transcription factors are recruited to
the glucose-6-phosphatase gene promoter in response to palmitate
in rat hepatocytes and H4IIE cells. J Nutr 137:554–559
46. Lee JY, Sohn KH, Rhee SH, Hwang D (2001) Saturated fatty
acids, but not unsaturated fatty acids, induce the expression of
cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol
Chem 276:16683–16689
47. Lee JY, Ye J, Gao Z, Lee WH, Zhao L, Sizemore L, Hwang DH
(2003) Reciprocal modulation of toll-like receptor-4 signaling
pathways involving My88 and phosphatidyinositol 3-kinase/AKT
by saturated and polyunsaturated fatty acids. J Biol Chem
278:37041–37051
48. Smith JG, Yokoyama WH, German JB (1998) Dietary butyric
acid: implications for gene expression. Crit Rev Food Sci Nutr
38:259–297
49. Han S, Lu J, Zhang Y, Cheng C, Li L, Han L, Huang B (2007)
HDAC inhibitors TSA and sodium butyrate enhanced the human
IL-5 expression by altering histone acetylation status at its pro-
moter region. Immunol Lett 108:143–150
50. Yu S, Derr J, Etherton TD, Kris-Etherton PM (1995) Plasma
cholesterol-predictive equations demonstrate that stearic is neu-
tral and monounsaturated fatty acids are hypocholesterolemic.
Am J Clin Nutr 61:1129–1139
51. Hunter JE, Zhang J, Kris-Etherton PM (2010) Cardiovascular
disease risk of dietary stearic acid compared with trans, other
saturated and unsaturated fatty acids : a systematic review. Am J
Clin Nutr 91:46–63
52. Bonanome A, Grundy SM (1988) Effect of dietary stearic acid on
plasma cholesterol and lipoprotein levels. N Engl J Med
318:1244–1248
53. Legrand P, Catheline D, Fichot MC, Lemarchal P (1997) Inhib-
iting delta9-desaturase activity impairs triacylglycerol secretion
in cultured chicken hepatocytes. J Nutr 127:249–256
54. Sampath H, Miyazaki M, Dobrzyn A, Ntambi JM (2007) Stea-
royl–CoA desaturase-1 mediates the pro-lipogenic effects of
dietary saturated fatty acids. J Biol Chem 282:2483–2493
55. Paillard F, Catheline D, Le Duff F, Bouriel M, Pouchard M,
Deugnier Y, Daubert JC, Legrand P et al (2008) D9-desaturase,
new candidate implied in the expression of triglyceridemia and
abdominal adiposity. Nutr Metab Cardiovasc Dis 18:436–440
56. Tholstrup T, Miller GJ, Bysted A, Sandstrom B (2003) Effect of
individual dietary fatty acids on postprandial activation of blood
coagulation factor VII and fibrinolysis in healthy young men. Am
J Clin Nutr 77:1125–1132
57. Thijssen MA, Hornstra G, Mensink RP (2005) Stearic, oleic and
linoleic acids have comparable effects on markers of thrombotic
tendency in healthy human subjects. J Nutr 135:2805–2811
58. Jan S, Guillou H, D’Andre´a S, Daval S, Bouriel M, Rioux V,
Legrand P (2004) Myristic acid increases D6-desaturase activity
in cultured rat hepatocytes. Reprod Nutr Dev 44:131–140
59. Rioux V, Catheline D, Bouriel M, Legrand P (2005) Dietary
myristic acid at physiologically relevant levels increases the tis-
sue content of C20:5n-3 and C20:3n-6 in the rat. Reprod Nutr
Dev 45:599–612
60. Dabadie H, Peuchant E, Bernard M, Le Ruyet P, Mendy F (2005)
Moderate intake of myristic acid in sn-2 position has beneficial
lipidic effects and enhances DHA of cholesteryl esters in an
interventional study. J Nutr Biochem 16:375–382
61. Dabadie H, Motta C, Peuchant E, Le Ruyet P, Mendy F (2006)
Variations in daily intakes of myristic and a-linolenic acids in sn-
2 position modify lipid profile and red blood cell membrane
fluidity. Br J Nutr 96:283–289
62. Borgese N, Aggujaro D, Carrera P, Pietrini G, Bassetti M (1996)
A role for N-myristoylation in protein targeting: NADH-cyto-
chrome b5 reductase requires myristic acid for association with
outer mitochondrial but not ER membranes. J Cell Biol
135:1501–1513
63. Chen J, Ghazawi FM, Bakkar W, Li Q (2006) Valproic acid and
butyrate induce apoptosis in human cancer cells through inhibi-
tion of gene expression of Akt/protein kinase B. Mol Cancer 5:71
64. Stempelj M, Kedinger M, Augenlicht L, Klampfer L (2007)
Essential role of the JAK/STAT1 signaling pathway in the
expression of inducible nitric-oxide synthase in intestinal epi-
thelial cells and its regulation by butyrate. J Biol Chem
282:9797–9804
65. Sengupta S, Muir JG, Gibson PR (2006) Does butyrate protect
from colorectal cancer? J Gastroenterol Hepatol 21:209–218
66. Belakavadi M, Prabhakar BT, Salimath BP (2007) Purification
and characterization of butyrate-induced protein phosphatase
involved in apoptosis of Ehrlich ascites tumor cells. Biochim
Biophys Acta 1770:39–47
67. Staiger K, Staiger H, Weigert C, Haas C, Haring HU, Kellerer M
(2006) Saturated, but not unsaturated, fatty acids induce apoptosis
of human coronary artery endothelial cells via nuclear factor-jB
activation. Diabetes 55:3121–3126
68. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T (2001)
Ceramide in apoptosis signaling: relationship with oxidative
stress. Free Radic Biol Med 31:717–728
69. Siskind LJ (2005) Mitochondrial ceramide and the induction of
apoptosis. J Bioenerg Biomembr 37:143–153
70. Stiban J, Fistere D, Colombini M (2006) Dihydroceramide hin-
ders ceramide channel formation: implications on apoptosis.
Apoptosis 11:773–780
71. Paumen MB, Ishida Y, Muramatsu M, Yamamoto M, Honjo T
(1997) Inhibition of carnitine palmitoyltransferase I augments
sphingolipid synthesis and palmitate-induced apoptosis. J Biol
Chem 272:3324–3329
72. Beauchamp E, Tekpli X, Marteil G, Lagadic-Gossmann D,
Legrand P, Rioux V (2009) N-Myristoylation targets dihydrocera-
mide Delta4-desaturase 1 to mitochondria: partial involvement in the
apoptotic effect of myristic acid. Biochimie 91:1411–1419
73. Geliebter A, Torbay N, Bracco ET, Hashim SA, Van Itallie TB
(1983) Overfeeding with medium chain triglyceride diet results in
diminished deposition of fat. Am J Clin Nutr 37:1–4
74. Tachibana S, Sato K, Cho Y, Chiba T, Schneider WJ, Akiba Y
(2005) Octanoate reduces very low-density lipoprotein secretion
by decreasing the synthesis of apolipoprotein B in primary cul-
tures of chicken hepatocytes. Biochim Biophys Acta 1737:36–43
946 Lipids (2010) 45:941–946
123
